Despite success with BRAFV600E inhibitors, therapeutic responses in patients with
metastatic melanoma are short-lived because of the acquisition of drug resistance. We …

Targeting multiple components of the MAPK pathway can prolong the survival of patients
with BRAFV600E melanoma. This approach is not curative, as some BRAF-mutated …

Abstract Treatment resistance in metastatic melanoma is a longstanding issue. Current
targeted therapy regimes in melanoma largely target the proliferating cancer population …

Vemurafenib/PLX4032, a selective inhibitor of mutant BRAFV600E, constitutes a paradigm
shift in melanoma therapy. Unfortunately, acquired resistance, which unavoidably occurs …

Clinically acquired resistance to MAPK inhibitor (MAPKi) therapies for melanoma cannot be
fully explained by genomic mechanisms and may be accompanied by co-evolution of intra …

Tumor heterogeneity is a major challenge for cancer treatment, especially due to the
presence of various subpopulations with stem cell or progenitor cell properties. In mouse …

Melanoma is the most aggressive form of skin cancer and, if spread outside the epidermis,
has a dismal prognosis. Before the approval of the anti-cytotoxic T lymphocyte-associated …

Targeted therapies as BRAF and MEK inhibitor combination have been approved as first-
line treatment for BRAF-mutant melanoma. However, disease progression occurs in most of …

Despite the recent success of MAPK signaling-targeted drugs in melanoma, the majority of
patients with metastatic melanoma still undergo disease progression after initial tumor …

Metastasis and failure of present-day therapies represent the most common causes of
mortality in patients with cutaneous melanoma. To identify the underlying genetic and …